-
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented data demonstrating that switching to…
Mar 17, 2025
-
ACTG PRESENTS IMPORTANT FINDINGS FROM REPRIEVE AT CROI 2025
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented findings from the REPRIEVE trial…
Mar 17, 2025
-
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today presented promising findings from a study…
Mar 17, 2025
-
ACTG PRESENTS FOUR STUDIES AT CROI DESCRIBING FINDINGS FROM SLIM LIVER
Presentations highlight relationship between semaglutide and blood markers of gene modification age predictors, gut bacteria, heart and metabolic effects, and…
Mar 17, 2025
-
ACTG ANNOUNCES PUBLICATION OF BEE-HIVE TRIAL IN JAMA
Dec 04, 2024
-
Jul 23, 2024
-
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Open and enrolling
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
A5243: Non-US Genomic Sampling
Collecting blood and saliva samples from former and current ACTG study participants for future HIV-related genetic testing. This is a…
Closed to accrual
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis
-
You are being asked to take part in this research study because you are infected with HIV, the virus that…
Closed to accrual
HIV comorbidities and complications
Participants will be followed for 366 weeks (7 years).
-
In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin)…
Closed to accrual
HIV comorbidities and complications
You will be in this study for about 36 to 96 months depending on when you enroll in the study.
-
A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)
Aging with HIV may be associated with an earlier development of frailty (weakness) or disability, including difficulties in tests of…
Closed to accrual
HIV comorbidities and complications
Participants will be followed for 48 months from the date of enrollment into A5332. Based on their date of enrollment into A5332, participants may be followed between 24 to 48 months.
-
About 30-40% of people living with HIV have a condition called NAFLD, or non-alcoholic fatty liver disease. NAFLD is caused…
Closed to accrual
HIV comorbidities and complications